Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-25
    E.g., 2018-02-25

Articles

Pages

171624 items
12:38 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Sanofi exercises option under Nanobody deal with Ablynx

Sanofi (Euronext:SAN; NYSE:SNY) exercised an option under a July 2017 deal with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) to receive exclusive global rights to develop and commercialize two multi-specific Nanobodies to treat immune mediated inflammatory diseases. Nanobodies...
12:38 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Google's deep-learning algorithm predicts CV risk

Google Inc. (Mountain View, Calif.) and colleagues reported that a deep-learning algorithm was able to use anatomical features such as the optic disc and blood vessels from retinal fundus photographs to predict cardiovascular risk factors....
12:37 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

J&J execs launch Centyrins newco Aro

Two former Johnson & Johnson (NYSE:JNJ) executives have co-founded Aro Biotherapeutics Co. (Philadelphia, Pa.) to develop Centyrins for extra-hepatic, receptor-mediated delivery of oligonucleotides and other payloads. Aro President and CEO Susan Dillon was previously global...
12:37 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Everest gets rights to Tetraphase antibiotic

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) granted C-Bridge-backed Everest Medicines Ltd. (Boston, Mass.) exclusive rights to develop and commercialize eravacycline (TP-434) in China, Taiwan, Hong Kong, Macau, South Korea and Singapore. Tetraphase will receive $7 million up front...
12:36 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Incyte and Hengrui end PD-1 mAb deal

Incyte Corp. (NASDAQ:INCY) said in an SEC document filed Feb. 15 that it and Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:3600276) agreed to terminate a deal for SHR-1210 (INCSHR1210), an anti-PD-1 mAb. In 2015, Hengrui granted Incyte...
12:36 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Organ-on-Chip company Emulate reveals new deals

Emulate Inc. (Cambridge, Mass.) announced partnerships with Roche (SIX:ROG; OTCQX:RHHBY) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) on Feb. 20, as well as an initiative with Cedars-Sinai Medical Center (Los Angeles, Calif.). The company's Organs-on-Chips are living,...
12:36 PM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Arix, Fosun in China-focused deal

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Fosun International Ltd. (HKSE:656) to invest in and build newcos focused on the China market. The deal will give Arix access to investment opportunities in China,...
12:36 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

FDA clears MabSpace's PD-L1 mAb for first-in-human trial

MabSpace Biosciences Co. Ltd. (Suzhou, China) said FDA approved an IND to begin a first-in-human trial of MSB2311 to treat advanced or metastatic solid tumors. MSB2311, a humanized IgG1 mAb targeting PD-L1, will be MabSpace's...
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Eli Lilly stops Phase II trial of BTK inhibitor in RA

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II RAjuvenate trial of HM71224 (LY3337641) to treat rheumatoid arthritis after a planned analysis showed that the difference between the active and placebo control arms "was not...
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Wilson Therapeutics starts Phase III of WTX101 for Wilson's disease

The single-blind, international trial will enroll about 100 patients. The primary endpoint is non-inferiority of WTX101 to standard of care on copper control as measured by the percentage change in free copper levels in blood...

Pages